Monitoring Recombinant Factor VIIa Treatment: Efficacy Depends on High Levels of Fibrinogen in a Model of Severe Dilutional Coagulopathy

Journal of Cardiothoracic and Vascular Anesthesia

Volumn 22, Issue 5, 2008, Pages 675-680

  Ganter, Michael T ^a   Schmuck, Saskia ^b   Hamiel, Christine R ^c   Wischmeyer, Paul E ^c   Heule, Daniela ^b   Zollinger, Andreas ^b   Hofer, Christoph K ^b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c UNIVERSITY OF COLORADO   (United States)

Author keywords

dilutional coagulopathy; fibrinogen concentrate; hemodilution; recombinant activated factor VII; ROTEM; Sonoclot analyzer; thromboelastography; thromboelastometry

Indexed keywords

RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANALYZER; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD SAMPLING; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; DILUTIONAL COAGULOPATHY; DISEASE SEVERITY; DRUG EFFICACY; FIBRINOGEN BLOOD LEVEL; FIBRINOGEN SYNTHESIS; HEMODILUTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LABORATORY TEST; MALE; MEDICAL ASSESSMENT; NORMAL HUMAN; POINT OF CARE TESTING; PRIORITY JOURNAL; THROMBOELASTOGRAPHY; VISCOELASTICITY;

ADULT; BLOOD COAGULATION TESTS; FACTOR VIIA; FIBRINOGEN; HEMODILUTION; HUMANS; MALE; POINT-OF-CARE SYSTEMS; RECOMBINANT PROTEINS;

EID: 52149111176     PISSN: 10530770     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.jvca.2008.01.017     Document Type: Article

References (35)

1. Levi M., Peters M., and Buller H.R. Efficacy and safety of recombinant factor VIIa for treatment of severe bleeding: A systematic review. Crit Care Med 33 (2005) 883-890
2. Boffard K.D., Riou B., Warren B., et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: Two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 59 (2005) 8-15
3. Shander A., Goodnough L.T., Ratko T., et al. Consensus recommendations for the off-label use of recombinant human factor VIIa (NovoSeven) therapy. Pharm Ther 30 (2005) 644-658
4. Vincent J.L., Rossaint R., Riou B., et al. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding-A European perspective. Crit Care 10 (2006) R120
5. Ganguly S., Spengel K., Tilzer L.L., et al. Recombinant factor VIIa: Unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome. Clin Lab Haematol 28 (2006) 309-312
6. Sorensen B., and Ingerslev J. Thromboelastography and recombinant factor VIIa-hemophilia and beyond. Semin Hematol 41 (2004) 140-144
7. Sorensen B., and Ingerslev J. Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2 (2004) 102-110
8. Kawaguchi C., Takahashi Y., Hanesaka Y., et al. The in vitro analysis of the coagulation mechanism of activated factor VII using thromboelastogram. Thromb Haemost 88 (2002) 768-772
9. Pusateri A.E., and Park M.S. Mechanistic implications for the use and monitoring of recombinant activated factor VII in trauma. Crit Care 9 suppl (2005) S15-S24
10. Engstrom M., Reinstrup P., and Schott U. An in vitro evaluation of standard rotational thromboelastography in monitoring of effects of recombinant factor VIIa on coagulopathy induced by hydroxyethyl starch. BMC Blood Disord 5 (2005) 3
11. Sorensen B., Johansen P., Christiansen K., et al. Whole blood coagulation thromboelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 1 (2003) 551-558
12. Rossaint R., Cerny V., Coats T.J., et al. Key issues in advanced bleeding care in trauma. Shock 26 (2006) 322-331
13. Hiippala S.T., Myllyla G.J., and Vahtera E.M. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. Anesth Analg 81 (1995) 360-365
14. Singbartl K., Innerhofer P., Radvan J., et al. Hemostasis and hemodilution: A quantitative mathematical guide for clinical practice. Anesth Analg 96 (2003) 929-935
15. Fenger-Eriksen C., Anker-Moller E., Heslop J., et al. Thromboelastographic whole blood clot formation after ex vivo addition of plasma substitutes: Improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth 94 (2005) 324-329
16. Fries D., Innerhofer P., Reif C., et al. The effect of fibrinogen substitution on reversal of dilutional coagulopathy: An in vitro model. Anesth Analg 102 (2006) 347-351
17. De L.C., Calatzis A., Welsch U., et al. Fibrinogen concentrate reverses dilutional coagulopathy induced in vitro by saline but not by hydroxyethyl starch 6%. Anesth Analg 102 (2006) 1194-1200
18. Fries D., Krismer A., Klingler A., et al. Effect of fibrinogen on reversal of dilutional coagulopathy: A porcine model. Br J Anaesth 95 (2005) 172-177
19. Egli G.A., Zollinger A., Seifert B., et al. Effect of progressive haemodilution with hydroxyethyl starch, gelatin and albumin on blood coagulation. Br J Anaesth 78 (1997) 684-689
20. Niemi T.T., Suojaranta-Ylinen R.T., Kukkonen S.I., et al. Gelatin and hydroxyethyl starch, but not albumin, impair hemostasis after cardiac surgery. Anesth Analg 102 (2006) 998-1006
21. Luddington R.J. Thromboelastography/thromboelastometry. Clin Lab Haematol 27 (2005) 81-90
22. Hett D.A., Walker D., Pilkington S.N., et al. Sonoclot analysis. Br J Anaesth 75 (1995) 771-776
23. Rivard G.E., Brummel-Ziedins K.E., Mann K.G., et al. Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thromboelastography. J Thromb Haemost 3 (2005) 2039-2043
24. Nielsen V.G. A comparison of the thromboelastograph and the ROTEM. Blood Coagul Fibrinolysis 18 (2007) 247-252
25. Ganter MT, Hofer CK: Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. Anesth Analg (in press)
26. Sorensen B., and Ingerslev J. Tailoring haemostatic treatment to patient requirements-An update on monitoring haemostatic response using thromboelastography. Haemophilia 11 suppl (2005) 1-6
27. Fries D., Haas T., Klingler A., et al. Efficacy of fibrinogen and prothrombin complex concentrate used to reverse dilutional coagulopathy-A porcine model. Br J Anaesth 97 (2006) 460-467
28. O'Connell K.A., Wood J.J., Wise R.P., et al. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA 295 (2006) 293-298
29. Lichtman A.D., Carullo V., Minhaj M., et al. Case 6-2007: Massive intraoperative thrombosis and death after recombinant activated factor VII administration. J Cardiothorac Vasc Anesth 21 (2007) 897-902
30. Warren O., Mandal K., Hadjianastassiou V., et al. Recombinant activated factor VII in cardiac surgery: A systematic review. Ann Thorac Surg 83 (2007) 707-714
31. Karkouti K., Beattie W.S., Crowther M.A., et al. The role of recombinant factor VIIa in on-pump cardiac surgery: Proceedings of the Canadian Consensus Conference. Can J Anaesth 54 (2007) 573-582
32. Martinowitz U., and Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: A report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost 3 (2005) 640-648
33. Sorensen B., Fenger-Eriksen C., and Ingerslev J. Recombinant factor VIIa fails to correct coagulopathy induced by haemodilution with colloid. Br J Anaesth 94 (2005) 862-863
34. Schreiber M.A., Holcomb J.B., Hedner U., et al. The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. J Trauma 53 (2002) 252-257
35. Sondeen J.L., Pusateri A.E., Hedner U., et al. Recombinant factor VIIa increases the pressure at which rebleeding occurs in porcine uncontrolled aortic hemorrhage model. Shock 22 (2004) 163-168